Title of article
Intravitreal administration of bevacizumab: pros and cons
Author/Authors
Dashti-Khavidaki, Simin tehran university of medical sciences tums - Faculty of Pharmacy, تهران, ايران , Abdollahi, Mohammad tehran university of medical sciences tums - Faculty of Pharmacy and Pharmaceutical Sciences Research Center, تهران, ايران
From page
1
To page
4
Abstract
Bevacizumab (Avastin®, Genethech, Inc.) is a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It was first approved by the US food and drug administration for metastatic colorectal cancer and subsequently for cervical/ovarian/fallopian tube cancers, glioblastoma, non-small cell lung cancer, and metastaic renal cell carcinoma [1]. Recently its offlabel use for age-related macular degeneration (AMD) has received extensive attention.
Journal title
Daru Journal of Pharmaceutical Sciences
Journal title
Daru Journal of Pharmaceutical Sciences
Record number
2634923
Link To Document